Harvard Bioscience Inc Cash Flow Conversion Efficiency
Harvard Bioscience Inc cash flow conversion efficiency. Based on the latest financial reports, Harvard Bioscience Inc (HBIO) has a cash flow conversion efficiency ratio of 0.044x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($323.00K) by net assets ($7.42 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Harvard Bioscience Inc (1999–2025)
Cash flow conversion efficiency of Harvard Bioscience Inc from 1999 to 2025. This chart illustrates how Harvard Bioscience Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View HBIO stock price for real-time trading data and today's change.
Harvard Bioscience Inc Cash Flow Conversion Ratio Explained
Harvard Bioscience Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Harvard Bioscience Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Harvard Bioscience Inc ranked by their cash flow conversion efficiency. Also see Harvard Bioscience Inc (HBIO) total market value for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Inventus Mining Corp
V:IVS
|
4.498x |
|
SMCG Co., Ltd.
KQ:460870
|
-0.045x |
|
Yiren Digital Ltd
F:19YA
|
0.040x |
|
Can Don Hydro Power JSC
VN:SJD
|
0.027x |
|
RESOLUTION MINERALS LTD
F:NC3
|
N/A |
|
Logistea A
ST:LOGI-A
|
0.020x |
|
CVRx Inc
NASDAQ:CVRX
|
-0.442x |
|
Cimbeton Hazirbeton ve Prefabrik Yapi Elemanlari Sanayi ve Ticaret AS
IS:CMBTN
|
0.316x |
Annual Cash Flow Conversion Efficiency for Harvard Bioscience Inc (1999–2025)
The table below shows the annual cash flow conversion efficiency of Harvard Bioscience Inc from 1999 to 2025. Review Harvard Bioscience Inc free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $13.73 Million | $6.73 Million | 0.490x | +2055.11% |
| 2024-12-31 | $63.34 Million | $1.44 Million | 0.023x | -88.16% |
| 2023-12-31 | $73.07 Million | $14.03 Million | 0.192x | +1103.48% |
| 2022-12-31 | $72.22 Million | $1.15 Million | 0.016x | +5.42% |
| 2021-12-31 | $83.40 Million | $1.26 Million | 0.015x | -87.56% |
| 2020-12-31 | $76.68 Million | $9.33 Million | 0.122x | +23.54% |
| 2019-12-31 | $81.69 Million | $8.05 Million | 0.099x | +245.36% |
| 2018-12-31 | $82.18 Million | $2.34 Million | 0.029x | +118.30% |
| 2017-12-31 | $80.90 Million | $1.06 Million | 0.013x | -82.48% |
| 2016-12-31 | $72.20 Million | $5.38 Million | 0.075x | +720.68% |
| 2015-12-31 | $77.60 Million | $705.00K | 0.009x | -80.07% |
| 2014-12-31 | $95.47 Million | $4.35 Million | 0.046x | +6.06% |
| 2013-12-31 | $94.48 Million | $4.06 Million | 0.043x | -44.46% |
| 2012-12-31 | $104.21 Million | $8.06 Million | 0.077x | +16.38% |
| 2011-12-31 | $95.50 Million | $6.35 Million | 0.066x | -51.20% |
| 2010-12-31 | $90.25 Million | $12.29 Million | 0.136x | -37.91% |
| 2009-12-31 | $75.26 Million | $16.51 Million | 0.219x | +59.05% |
| 2008-12-31 | $66.72 Million | $9.20 Million | 0.138x | -15.18% |
| 2007-12-31 | $74.14 Million | $12.05 Million | 0.163x | +39.88% |
| 2006-12-31 | $71.88 Million | $8.36 Million | 0.116x | +53.09% |
| 2005-12-31 | $68.42 Million | $5.20 Million | 0.076x | -30.72% |
| 2004-12-31 | $104.36 Million | $11.44 Million | 0.110x | +434.44% |
| 2003-12-31 | $98.88 Million | $2.03 Million | 0.021x | +126.72% |
| 2002-12-31 | $88.38 Million | $799.46K | 0.009x | -85.24% |
| 2001-12-31 | $66.81 Million | $4.10 Million | 0.061x | +49.49% |
| 2000-12-31 | $52.33 Million | $2.15 Million | 0.041x | -88.81% |
| 1999-12-31 | $7.98 Million | $2.93 Million | 0.367x | -- |
About Harvard Bioscience Inc
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrop… Read more